» Articles » PMID: 618906

Antibody-dependent Cellular Cytotoxicity in Primary Immunodeficiency Diseases and with Normal Leukocyte Subpopulations. Importance of the Type of Target

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1978 Jan 1
PMID 618906
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

To gain insight into a possible role for antibody-dependent cell-mediated cytotoxicity in vivo, we examined the ability of leukocytes from 28 patients with primary immunodeficiency and from 20 normal controls to lyse three different types of antibody-coated targets in vitro. Mean cytotoxic indices +/-1 SD elicited by unfractionated mononuclear cells from normal controls were 28.74+/-13.26 for human HLA antibody-coated lymphocyte targets, 42.79+/-8.27 for rabbit IgG antibody-coated chicken erythrocyte targets, and 47.58+/-10.34 for human anti-CD (Ripley)-coated O+ erythrocyte targets. Significantly (P=<0.05) lower than normal mean cytotoxic indices against lymphocyte targets were seen with effector cells from 10 patients with X-linked agammaglobulinemia (3.7+/-4.33), in 10 with common variable agammaglobulinemia (16.05+/-7.74), in 3 with immunodeficiency with hyper IgM (18.41+/-4.88), and in 2 with severe combined immunodeficiency (3.94+/-0.3). Antibody-dependent cytotoxicity against chicken erythrocytes was significantly (P=<0.05) lower than normal only in the common variable agammaglobulinemic group (33.33+/-12.3) and against human erythrocytes only in the common variable (34.36+/-9.59) and hyper IgM (27.54+/-0.66) groups. Rosette and anti-F(ab')(2) depletion studies with normal leukocytes indicated that a nonadherent, nonphagocytic, non-Ig-bearing, non-C receptor-bearing, Fc receptor-bearing lymphocyte was the only effector capable of lysing HLA antiboyd-coated lymphocyte targets. Patients with infantile X-linked agammaglobulinemia and severe combined immunodeficiency appear to have a marked deficiency in this type of effector cell function.

Citing Articles

Production of reactive oxygen metabolites induced by asbestos fibres in human polymorphonuclear leucocytes.

Hedenborg M, Klockars M J Clin Pathol. 1987; 40(10):1189-93.

PMID: 3680543 PMC: 1141193. DOI: 10.1136/jcp.40.10.1189.


Rapid protein A assay for intrinsic factor and its binding antibody.

Sourial N J Clin Pathol. 1988; 41(5):568-72.

PMID: 3384987 PMC: 1141514. DOI: 10.1136/jcp.41.5.568.


Guidelines on the investigation and management of thrombophilia. The British Committee for Standards in Haematology.

J Clin Pathol. 1990; 43(9):703-9.

PMID: 2212062 PMC: 502744. DOI: 10.1136/jcp.43.9.703.


Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells.

Shaw G, Levy P, LoBuglio A J Clin Invest. 1978; 62(6):1172-80.

PMID: 748372 PMC: 371881. DOI: 10.1172/JCI109236.


Re-examination of the EA rosette assay (Ripley) for Fc receptor leucocytes.

Shaw G, Levy P, LoBuglio A Clin Exp Immunol. 1979; 36(3):496-501.

PMID: 487649 PMC: 1537757.


References
1.
Schiff R, Buckley R, Gilbertsen R, METZGAR R . Membrane receptors and in vitro responsiveness of lymphocytes in human immunodeficiency. J Immunol. 1974; 112(1):376-86. View

2.
Jondal M, Wigzell H, Aiuti F . Human lymphocyte subpopulations: classification according to surface markers and-or functional characteristics. Transplant Rev. 1973; 16:163-95. DOI: 10.1111/j.1600-065x.1973.tb00120.x. View

3.
Wisloff F, Froland S, Michaelsen T . Antibody-dependent cytotoxicity mediated by human Fc-receptor-bearing cells lacking markers for B- and T-lymphocytes. Int Arch Allergy Appl Immunol. 1974; 47(1):139-54. DOI: 10.1159/000231208. View

4.
Wisloff F, Froland S . Antibody-dependent lymphocyte-mediated cytotoxicity in man: no requirement for lymphocytes with membrane-bound immunoglobulin. Scand J Immunol. 1973; 2(2):151-7. DOI: 10.1111/j.1365-3083.1973.tb02026.x. View

5.
Chess L, Macdermott R, Schlossman S . Immunologic functions of isolated human lymphocyte subpopulations. I. Quantitative isolation of human T and B cells and response to mitogens. J Immunol. 1974; 113(4):1113-21. View